Cimetidine

CHEMBL30 Phase 4 承認済み Small molecule

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

252.3 g/mol

LogP

0.4

Phase

4

A first-generation H2 receptor antagonist that reduces gastric acid secretion by blocking histamine H2 receptors on parietal cells, used for peptic ulcer disease, gastroesophageal reflux disease, and pathological hypersecretory conditions. It is a potent inhibitor of several cytochrome P450 enzymes, leading to clinically significant drug interactions with many medications. It has largely been superseded by proton pump inhibitors for most acid-reducing indications.

分子量

252.3400 g/mol

LogP

0.40

TPSA

114.00 Å²

リピンスキーの五則

適合

治療領域

Ovarian Cancer Non-Small Cell Lung Cancer Rheumatoid Arthritis Osteoporosis Chronic Obstructive Pulmonary Disease Generalized Anxiety Disorder Melanoma Gastroesophageal Reflux Disease Chronic Kidney Disease Breast Cancer Atopic Dermatitis Leukemia

作用機序

Irreversibly inhibits the hydrogen-potassium ATPase (proton pump) on the apical surface of gastric parietal cells. This blocks the final common pathway of gastric acid secretion, producing profound and sustained acid suppression.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

機序

Irreversibly inhibits the hydrogen-potassium ATPase (proton pump) on the apical surface of gastric parietal cells. This blocks the final common pathway of gastric acid secretion, producing profound and sustained acid …

2D構造

SVG PNG

Cite this structure

Embed this structure

SMILES

CN/C(=N\CCSCc1nc[nH]c1C)NC#N

InChI

InChI=1S/C10H16N6S/c1-8-9(16-7-15-8)5-17-4-3-13-10(12-2)14-6-11/h7H,3-5H2,1-2H3,(H,15,16)(H2,12,13,14)

Molecular Formula

C10H16N6S

HBD / HBA

3 / 4

回転可能結合数

7

重原子数

17

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

よくある質問

A first-generation H2 receptor antagonist that reduces gastric acid secretion by blocking histamine H2 receptors on parietal cells, used for peptic ulcer disease, gastroesophageal reflux disease, and pathological hypersecretory conditions. It is a potent inhibitor of several cytochrome P450 enzymes, leading to clinically significant drug interactions with many medications. It has largely been superseded by proton pump inhibitors for most acid-reducing indications.

Irreversibly inhibits the hydrogen-potassium ATPase (proton pump) on the apical surface of gastric parietal cells. This blocks the final common pathway of gastric acid secretion, producing profound and sustained acid suppression.

Yes, Cimetidine is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL30. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 2756. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

PillFYI

患者向けのわかりやすい情報をお探しですか？

Cimetidine PillFYIで

構造

クイックデータ

分子式: C10H16N6S
同義語: 6

外部リンク

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

医学的免責事項

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.